Free Trial
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

Autolus Therapeutics logo
$2.31 -0.10 (-3.96%)
As of 01:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Key Stats

Today's Range
$2.23
$2.36
50-Day Range
$1.54
$2.68
52-Week Range
$1.11
$5.00
Volume
878,464 shs
Average Volume
1.76 million shs
Market Capitalization
$613.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.32
Consensus Rating
Buy

Company Overview

Autolus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

AUTL MarketRank™: 

Autolus Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 576th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Autolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Autolus Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Autolus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Autolus Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Autolus Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Autolus Therapeutics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Autolus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.91% of the float of Autolus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Autolus Therapeutics has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Autolus Therapeutics has recently increased by 7.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Autolus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Autolus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.91% of the float of Autolus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Autolus Therapeutics has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Autolus Therapeutics has recently increased by 7.55%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Autolus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 5 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Autolus Therapeutics' insider trading history.
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
See More Headlines

AUTL Stock Analysis - Frequently Asked Questions

Autolus Therapeutics' stock was trading at $2.35 at the beginning of 2025. Since then, AUTL shares have decreased by 3.2% and is now trading at $2.2750.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The firm had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million.
Read the conference call transcript
.

Autolus Therapeutics (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Autolus Therapeutics' top institutional investors include Atle Fund Management AB (0.42%), Perpetual Ltd (0.31%), Aubrey Capital Management Ltd (0.17%) and Privium Fund Management B.V. (0.11%).

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
5/08/2025
Today
8/01/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUTL
CIK
1730463
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$6.00
Potential Upside/Downside
+309.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$220.66 million
Net Margins
N/A
Pretax Margin
-2,600.95%
Return on Equity
-52.82%
Return on Assets
-29.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.24
Quick Ratio
9.02

Sales & Book Value

Annual Sales
$10.12 million
Price / Sales
59.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
1.41

Miscellaneous

Outstanding Shares
266,140,000
Free Float
197,743,000
Market Cap
$605.47 million
Optionable
Optionable
Beta
1.81
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:AUTL) was last updated on 8/1/2025 by MarketBeat.com Staff
From Our Partners